• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

考虑药代动力学变异性的抗菌药物断点估计

Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics.

作者信息

Bi Goue Denis Gohore, Li Jun, Nekka Fahima

机构信息

Faculté de Pharmacie, Université de Montréal, Montréal, Québec, Canada.

出版信息

Theor Biol Med Model. 2009 Jun 26;6:10. doi: 10.1186/1742-4682-6-10.

DOI:10.1186/1742-4682-6-10
PMID:19558679
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2709609/
Abstract

BACKGROUND

Pharmacokinetic and pharmacodynamic (PK/PD) indices are increasingly being used in the microbiological field to assess the efficacy of a dosing regimen. In contrast to methods using MIC, PK/PD-based methods reflect in vivo conditions and are more predictive of efficacy. Unfortunately, they entail the use of one PK-derived value such as AUC or Cmax and may thus lead to biased efficiency information when the variability is large. The aim of the present work was to evaluate the efficacy of a treatment by adjusting classical breakpoint estimation methods to the situation of variable PK profiles.

METHODS AND RESULTS

We propose a logical generalisation of the usual AUC methods by introducing the concept of "efficiency" for a PK profile, which involves the efficacy function as a weight. We formulated these methods for both classes of concentration- and time-dependent antibiotics. Using drug models and in silico approaches, we provide a theoretical basis for characterizing the efficiency of a PK profile under in vivo conditions. We also used the particular case of variable drug intake to assess the effect of the variable PK profiles generated and to analyse the implications for breakpoint estimation.

CONCLUSION

Compared to traditional methods, our weighted AUC approach gives a more powerful PK/PD link and reveals, through examples, interesting issues about the uniqueness of therapeutic outcome indices and antibiotic resistance problems.

摘要

背景

药代动力学和药效学(PK/PD)指标在微生物学领域越来越多地用于评估给药方案的疗效。与使用最低抑菌浓度(MIC)的方法不同,基于PK/PD的方法反映体内情况,并且对疗效更具预测性。不幸的是,它们需要使用一个源自药代动力学的数值,如曲线下面积(AUC)或峰浓度(Cmax),因此当变异性很大时,可能会导致效率信息有偏差。本研究的目的是通过调整经典的断点估计方法以适应药代动力学特征可变的情况,来评估一种治疗方法的疗效。

方法与结果

我们通过引入PK曲线“效率”的概念,对常用的AUC方法进行了合理的推广,其中涉及将疗效函数作为权重。我们针对浓度依赖性和时间依赖性两类抗生素制定了这些方法。使用药物模型和计算机模拟方法,我们为在体内条件下表征PK曲线的效率提供了理论基础。我们还利用药物摄入可变的特殊情况来评估所产生的可变PK曲线的影响,并分析对断点估计的影响。

结论

与传统方法相比,我们的加权AUC方法给出了更强有力的PK/PD联系,并通过实例揭示了关于治疗结果指标的唯一性和抗生素耐药性问题的有趣问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90d8/2709609/c107df2bffcf/1742-4682-6-10-8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90d8/2709609/6968d63064d5/1742-4682-6-10-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90d8/2709609/220848d020e0/1742-4682-6-10-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90d8/2709609/b6d4805f9279/1742-4682-6-10-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90d8/2709609/d1429ae51927/1742-4682-6-10-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90d8/2709609/7c112374a8ea/1742-4682-6-10-5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90d8/2709609/94631edf0930/1742-4682-6-10-6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90d8/2709609/ae7b3a846e47/1742-4682-6-10-7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90d8/2709609/c107df2bffcf/1742-4682-6-10-8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90d8/2709609/6968d63064d5/1742-4682-6-10-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90d8/2709609/220848d020e0/1742-4682-6-10-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90d8/2709609/b6d4805f9279/1742-4682-6-10-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90d8/2709609/d1429ae51927/1742-4682-6-10-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90d8/2709609/7c112374a8ea/1742-4682-6-10-5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90d8/2709609/94631edf0930/1742-4682-6-10-6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90d8/2709609/ae7b3a846e47/1742-4682-6-10-7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90d8/2709609/c107df2bffcf/1742-4682-6-10-8.jpg

相似文献

1
Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics.考虑药代动力学变异性的抗菌药物断点估计
Theor Biol Med Model. 2009 Jun 26;6:10. doi: 10.1186/1742-4682-6-10.
2
A proposal of a pharmacokinetic/pharmacodynamic (PK/PD) index map for selecting an optimal PK/PD index from conventional indices (AUC/MIC, Cmax/MIC, and TAM) for antibiotics.一项关于药代动力学/药效学(PK/PD)指数图的提议,用于从抗生素的传统指数(AUC/MIC、Cmax/MIC和TAM)中选择最佳PK/PD指数。
Drug Metab Pharmacokinet. 2014;29(6):455-62. doi: 10.2133/dmpk.DMPK-14-RG-013. Epub 2014 Jul 8.
3
Combatting the Rising Tide of Antimicrobial Resistance: Pharmacokinetic/Pharmacodynamic Dosing Strategies for Maximal Precision.对抗日益严重的抗微生物药物耐药性:最大精度的药代动力学/药效学给药策略。
Int J Antimicrob Agents. 2021 Mar;57(3):106269. doi: 10.1016/j.ijantimicag.2020.106269. Epub 2020 Dec 23.
4
How can we predict bacterial eradication?我们如何预测细菌清除情况?
Int J Infect Dis. 2003 Mar;7 Suppl 1:S13-20. doi: 10.1016/s1201-9712(03)90066-x.
5
The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.药代动力学和药效学模型在定义断点中的综合应用。
Infection. 2005 Dec;33 Suppl 2:29-35. doi: 10.1007/s15010-005-8205-z.
6
Pharmacodynamics: relation to antimicrobial resistance.药效学:与抗菌药物耐药性的关系
Am J Infect Control. 2006 Jun;34(5 Suppl 1):S38-45; discussion S64-73. doi: 10.1016/j.ajic.2006.05.227.
7
Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters.利用药代动力学和药效学参数优化抗菌治疗
Clin Microbiol Infect. 2001 Nov;7(11):589-96. doi: 10.1046/j.1198-743x.2001.00295.x.
8
New concept and a theoretical consideration of the mechanism-based pharmacokinetics/ pharmacodynamics (PK/PD) modeling for antimicrobial agents.抗菌药物基于机制的药代动力学/药效学(PK/PD)建模的新概念与理论思考
Jpn J Antibiot. 2008 Oct;61(5):314-38.
9
Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies.抗菌药物的合理给药:药代动力学和药效学策略
Am J Health Syst Pharm. 2009 Jun 15;66(12 Suppl 4):S23-30. doi: 10.2146/090087d.
10
Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents.抗菌药物药代动力学/药效学(PK/PD)分析的应用
J Infect Chemother. 2015 May;21(5):319-29. doi: 10.1016/j.jiac.2015.02.001. Epub 2015 Feb 12.

引用本文的文献

1
Unraveling Antimicrobial Resistance Dynamics in Mycoplasma gallisepticum: Insights Into Antibiotic and Disinfectant Interactions.解析鸡毒支原体的抗菌药物耐药动态:抗生素与消毒剂相互作用的见解
Vet Med Sci. 2025 Jan;11(1):e70181. doi: 10.1002/vms3.70181.
2
Reduced treatment frequencies with bumped kinase inhibitor 1369 are effective against porcine cystoisosporosis. bumped 激酶抑制剂 1369 减少治疗频率可有效对抗猪囊虫病。
Int J Parasitol Drugs Drug Resist. 2020 Dec;14:37-45. doi: 10.1016/j.ijpddr.2020.08.005. Epub 2020 Aug 21.
3
Pharmacokinetics of a peroral single dose of two long-acting formulations and an aqueous formulation of doxycycline hyclate in horses.

本文引用的文献

1
Assessing pharmacokinetic variability directly induced by drug intake behaviour through development of a feeding behaviour-pharmacokinetic model.
J Theor Biol. 2008 Apr 7;251(3):468-79. doi: 10.1016/j.jtbi.2007.11.033. Epub 2007 Dec 3.
2
Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects.基于机制的抗菌药物效应药代动力学-药效学建模
J Pharmacokinet Pharmacodyn. 2007 Dec;34(6):727-51. doi: 10.1007/s10928-007-9069-x. Epub 2007 Sep 29.
3
Setting and revising antibacterial susceptibility breakpoints.设定和修订抗菌药物敏感性断点
给马口服单剂两种长效制剂和盐酸多西环素水混悬液的药代动力学。
Acta Vet Scand. 2013 Mar 8;55(1):21. doi: 10.1186/1751-0147-55-21.
Clin Microbiol Rev. 2007 Jul;20(3):391-408, table of contents. doi: 10.1128/CMR.00047-06.
4
A pharmacokinetic formalism explicitly integrating the patient drug compliance.一种明确整合患者药物依从性的药代动力学形式。
J Pharmacokinet Pharmacodyn. 2007 Feb;34(1):115-39. doi: 10.1007/s10928-006-9036-y. Epub 2006 Oct 12.
5
Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines.包括甘氨酰环素在内的四环素类药物的药代动力学和药效学。
J Antimicrob Chemother. 2006 Aug;58(2):256-65. doi: 10.1093/jac/dkl224. Epub 2006 Jul 1.
6
Guidelines for prudent use of antimicrobials and their implications on antibiotic usage in veterinary medicine.谨慎使用抗菌药物的指南及其对兽医学中抗生素使用的影响。
Int J Med Microbiol. 2006 Jun;296 Suppl 41:33-8. doi: 10.1016/j.ijmm.2006.01.059.
7
Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists.蒙特卡洛模拟在药敏折点评估中的应用:预测未来:传染病药师协会的见解
Pharmacotherapy. 2006 Jan;26(1):129-34. doi: 10.1592/phco.2006.26.1.129.
8
Who defines resistance? The clinical and economic impact of antimicrobial susceptibility testing breakpoints.谁来定义耐药性?抗菌药物敏感性试验折点的临床和经济影响。
Semin Pediatr Infect Dis. 2004 Apr;15(2):105-8. doi: 10.1053/j.spid.2004.01.014.
9
Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections.药代动力学和药效学在呼吸道感染抗菌治疗中的应用。
Clin Lab Med. 2004 Jun;24(2):477-502. doi: 10.1016/j.cll.2004.03.009.
10
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.抗感染药物的药代动力学和药效学问题:杀菌曲线与最低抑菌浓度
Antimicrob Agents Chemother. 2004 Feb;48(2):369-77. doi: 10.1128/AAC.48.2.369-377.2004.